Shots:

• Welldoc to receive $15M upfront- development & commercialization milestones and royalties on sales. Astellas and Welldoc will jointly develop and commercialize BlueStar for patients with diabetes in Asian countries including Japan
• The companies will co-develop & co-commercialize digital therapies globally for multiple therapeutic areas. The collaboration allows Welldoc to widen its platform in other therapeutic areas and expand its presence in global markets including the US while allowing Astellas to develop its Rx+ programs
• Welldoc’s BlueStar is a digital health solution that assists patients aged ≥18yrs. in managing their diabetes (T1D- T2D) and utilizes machine learning to aid self-management of diabetes and has received FDA’s approval in 2010 following 6 additional 510(k) clearances from the US FDA

Source1- Source2 to­ read full press release/ article 

Ref: Astellas- Welldoc | Image:  Astellas